Langerhans Cell Histiocytosis clinical trials
14 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
- Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
- Mirdametinib in Histiocytic Disorders
- Q702 for the Treatment of Patients With Hematologic Malignancies
- Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
- In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
- Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
- Histiocytic Disorder Follow-up Study
- Supportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic Diseases
- Project: Every Child for Younger Patients With Cancer
- International Rare Histiocytic Disorders Registry (IRHDR)
- Role of Genetic Factors in the Development of Lung Disease
- Pediatric Long-Term Follow-up and Rollover Study
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Langerhans Cell Histiocytosis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.